Table 3 |
||||
|
Immunostaining results of other markers studied. |
||||
|
ECA |
EMMA |
p-value |
||
|
|
||||
|
ER |
Score 0–3 |
11/14 (79%) |
1/18 (6%) |
<0.001 |
|
Score 4–12 |
3/14 (21%) |
17/18 (94%) |
||
|
Median (Range) |
0 (0–12) |
7.5 (2–12) |
<0.001 |
|
|
PR |
Score 0–3 |
11/14 (79%) |
2/18 (11%) |
<0.001 |
|
Score 4–12 |
3/14 (21%) |
16/18 (89%) |
||
|
Median (Range) |
0 (0–12) |
9 (1–12) |
<0.001 |
|
|
Vim |
Score 0–3 |
13/14 (93%) |
9/18 (50%) |
0.01 |
|
Score 4–12 |
1/14 (7%) |
9/18 (50%) |
||
|
Median (Range) |
0 (0–2) |
1.5 (0–9) |
0.002 |
|
|
|
||||
|
ECA, endocervical adenocarcinoma; EMMA, endometrial mucinous adenocarcinoma; NS, not significant. |
||||
|
Khoury et al. BMC Clinical Pathology 2006 6:1 doi:10.1186/1472-6890-6-1 |
||||